U.S. markets open in 3 hours 32 minutes
  • S&P Futures

    4,341.25
    -0.25 (-0.01%)
     
  • Dow Futures

    34,031.00
    -24.00 (-0.07%)
     
  • Nasdaq Futures

    14,174.75
    +16.25 (+0.11%)
     
  • Russell 2000 Futures

    1,964.00
    -8.70 (-0.44%)
     
  • Crude Oil

    87.55
    +0.20 (+0.23%)
     
  • Gold

    1,813.10
    -16.60 (-0.91%)
     
  • Silver

    23.32
    -0.49 (-2.05%)
     
  • EUR/USD

    1.1192
    -0.0053 (-0.47%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    30.60
    -0.56 (-1.80%)
     
  • GBP/USD

    1.3408
    -0.0055 (-0.41%)
     
  • USD/JPY

    115.1490
    +0.4890 (+0.43%)
     
  • BTC-USD

    36,411.11
    -1,494.22 (-3.94%)
     
  • CMC Crypto 200

    829.68
    -26.13 (-3.05%)
     
  • FTSE 100

    7,504.35
    +34.57 (+0.46%)
     
  • Nikkei 225

    26,170.30
    -841.03 (-3.11%)
     

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ABCL

VANCOUVER, September 10, 2021--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time.

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210910005540/en/

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Neil Berkley, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116